

OTC Markets

Joining us today is Dr. Carolyn Myers, the CEO of FendX Technologies that trades on our OTCQB Venture Market under the ticker F D X T F based in Canada. FendX is a nanotechnology company, focused on reducing the spread of pathogens to keep surfaces safe from contamination. Carolyn, thanks so much for joining us today.

Dr. Carolyn Myers

Ah, it's great to be here Cecilia. Thank you.

OTC Markets

Absolutely. So to start, tell us a bit about your professional background and how you got involved with FendX.

Dr. Carolyn Myers

Sure. Well I've been in the pharmaceutical industry for a number of years but mostly in senior roles in large cap companies in the United States and I'm very experienced in creating leading and growing businesses. And very much an entrepreneur I was the president of two businesses; one was revenue generating, the other development. And the revenue generating company while I was the president, grew even more than 25% annually and it was a real success. And um, in my tenure I've also launched more than 25 products in the US and around the world and done more than 50 million licensing transactions and I've been involved in working with startups for micro-cap companies for a number of years now and that's how I fell onto the nanotechnology and said this stuff is really cool. We need to build a company around it which is what we ultimately did and that's how I ended up becoming the CEO of FendX.

OTC Markets

Give us an overview of your lead product under development: REPELWRAP™.

Dr. Carolyn Myers

Yeah, so REPELWRAP™ film as you say is our lead product and development. Um, when you apply it as a film to surfaces it instantly protects them from contamination and the way it works is that the surface is where the nanotechnology is. And that surface has repelling properties that prevent bacteria and viruses from sticking to it and because they can't stick. They can't replicate and as a consequence of that generally speaking, they can't get transferred from person to person or from surface to surface. Um, where we are with REPELWRAP™ film right now is we've transferred it to our manufacturing partner who has confirmed that they can reproduce the film in their lab and now are gearing up to conduct a run on their commercial manufacturing lines to create intermediate size samples for testing, to ensure that they still have the repelling specifications we want them to have and if

they do, we'll move into a commercial scale at manufacturing and with the intent of eventually moving into launching the product and right now we estimate that if everything goes as planned, we potentially could be in the Canadian Market by mid 2024 focused on Health Care as well as other high traffic, high touch industries and we plan to sell the product through distributors or work with them to get into hospitals and other venues.

OTC Markets

How did the COVID pandemic influence your business strategy and growth?

Dr. Carolyn Myers

Well, you know it's interesting Cecilia because this nanotechnology was actually created before COVID it was actually created because of the concern of healthcare acquired infections which is one of the top leading causes of death. I don't know if you know this but in the United States, annually more than 99,000 people die and it costs the healthcare system a significant amount of money annually, well above twenty-five billion so that was the impetus for creating this nanotechnology. But of course you know we're now on the heels of COVID and there is significant heightened awareness, I mean for many of us is the first time we've experienced such a very virulent bug like COVID and in addition, we realize that we're very vulnerable and you know, many of us have changed our habits. We're much as they say have much higher heightened awareness and we have a general sense of being more conscious of our hygiene, of the hygienic environment around us. So I think it positions us really well as we bring our products to market in the future and interestingly when the pandemic hit, we did test COVID light viruses on our surfaces and we got really great results through mcmaster showing that it reduced adherence significantly um by more than 99% so we know that we can, you know, fight against these viruses as well and potentially reduce their transmission.

OTC Markets

What is in your product development pipeline?

Dr. Carolyn Myers

We recently unlicensed additional nanotechnology from McMaster. It's actually a spray version of REPELWRAP™ film. Essentially if you take this spray, and you spray it onto a surface, it forms a film coating on that surface which is what provides the protection from contamination. So it works very similarly to REPELWRAP™ film but you spray it on as opposed to putting a film on a surface. But additionally and very exciting to us is that not only does our spray repel bugs, but if there's any bugs remaining on the surface, it will also kill them and so it has dual properties repelling as well as killing. You know, while this product is still early in development, we do believe it is an important addition to our pipeline because we do anticipate that it will

be easy to apply to many more surfaces than the film and has the potential to expand our market opportunities and in the near term, next couple of quarters. The other one and a very exciting project is coding catheters. Ah, it has been shown by McMaster that if you take the nanotechnology and you basically coat plastic similar to catheters that they can reduce significantly the formation of bacterial colonies and also reduce blood clotting. Which are the two culprits that are responsible for occluding catheters. So, we see this as potentially very important to us as we move forward and develop our pipeline because if we can show that we can reduce biofilm formation and clod formation that we might potentially be able to fight against these in long term in dwelling catheters that have a tendency to occlude and can cause the health care system a lot of money to manage.

OTC Markets

As you are cross traded on the CSE and the OTCQB Venture Market, talk about your goals for expanding your U.S investor base.

Dr. Carolyn Myers

Well, we're pretty excited to get on the OTCQB Venture Market and you know the next step as you know was to get OTC eligibility which we very recently got so our plan now is to commence a very comprehensive campaign to reach as many potential investors as we possibly can in the United States you know what this will entail. Yeah, reaching out to potential investors through you know, social and digital media platforms and other sorts of communication like newsletters. Attending conferences, conducting webinars, creating podcasts just like we're doing here and then other you know activities that are going to really help us focus on building awareness about the company and what we're doing with US investors.

OTC Markets

Well Carolyn, I really appreciate your time today and the updates and look forward to talking to you very soon again.

Dr. Carolyn Myers

Well thanks Cecilia I really appreciate. It's been fun talking to you and I just want to close by encouraging our listeners to visit our website. It's fendextech.com Where you can find our investor deck. You can find our fact sheet as well as you can sign up to receive e-blasts from us and also yeah I encourage you to follow us on Twitter, LinkedIn and Facebook where we post most of the information that we put out publicly. So thanks again. Cecilia.

OTC Markets

Absolutely FendX Technologies trades under the symbol F D X T F on our OTCQB Venture Market.

**This is an autogenerated transcript and may contain typos.*